Berenberg Bank Sticks to Their Buy Rating for ATAI Life Sciences (ATAI)

In a report released today, Caroline Palomeque from Berenberg Bank maintained a Buy rating on ATAI Life Sciences (ATAIResearch Report), with a price target of $18.00. The company’s shares opened today at $1.50.

According to TipRanks, Palomeque is an analyst with an average return of -15.2% and a 27.59% success rate. Palomeque covers the Healthcare sector, focusing on stocks such as Denali Therapeutics, Ascendis Pharma, and Anavex Life Sciences.

ATAI Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $22.71, representing a 1,414.00% upside. In a report released today, EF Hutton also maintained a Buy rating on the stock with a $15.00 price target.

See today’s best-performing stocks on TipRanks >>

ATAI market cap is currently $436.3M and has a P/E ratio of -2.11.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine.

Read More on ATAI:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed